Mandate

Acquisition of Alvedon approved

April 07, 2009

The Swedish Competition Authority has, following an in-depth investigation, on 3 April 2009 cleared GlaxoSmithKline’s acquisition of a portfolio of drugs, including i.a. the brand Alvedon, from AstraZeneca.

Alvedon is the leading painkiller brand in Sweden. GlaxoSmithKline controlled already prior to the acquisition Panodil, one of the main competing brands. The transaction was notified by the parties on 22 December 2008.
The Competition Authority carried out an extensive market investigation and retained external expertise to simulate the effects of the combination.

“Although the transaction involved a strong market position in painkillers based on paracetamol, the Competition Authority could eventually conclude that the transaction did not significantly impede the existence or development of effective competition. The Competition Authority’s decision is, of course, satisfactory for the parties but also of principle importance”, says Johan Karlsson, responsible partner for Vinge’s competition team, who acted for AstraZeneca.

“It is one of the few cases where efficiencies made a real difference for the outcome. The decision also shows that the Competition Authority, which it should do, could also take into account future changes in the market place, in this case the liberalization of the pharmaceutical market.”

Vinge advised AstraZeneca. Vinge’s competition team included Johan Karlsson (responsible partner), Mattias Ganslandt (economist), Per Karlsson (counsel), Peter Alstergren (associate) and Carl Johan Sundqvist (associate).   

Related

Vinge has advised Pareto Securities in connection with a rights issue in Episurf Medical

Vinge has advised Pareto Securities in connection with a partially secured rights issue of units of up to approximately SEK 120 million in Episurf Medical.
April 24, 2024

Vinge has advised Embracer Group in connection with a EUR 900 million bridge facility agreement entered into with JP Morgan, BNP Paribas, SEB, Société Générale and Swedbank

Vinge has advised Embracer Group AB (publ) (“Embracer”) and its subsidiary group Asmodee in connection with the entry into of a EUR 900,000,000 financing agreement with JP Morgan, BNP Paribas, SEB, Société Générale and Swedbank and concurrent prepayment of existing Embracer indebtedness.
April 22, 2024

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024